

# Robin E Norris

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6505775/publications.pdf>

Version: 2024-02-01

14  
papers

219  
citations

1684188

5  
h-index

1125743

13  
g-index

14  
all docs

14  
docs citations

14  
times ranked

327  
citing authors

#	ARTICLE	IF	CITATIONS
1	Adherence and Barriers to Inpatient Physical Therapy Among Adolescents and Young Adults with Hematologic Malignancies. <i>Journal of Adolescent and Young Adult Oncology</i> , 2022, 11, 605-610.	1.3	2
2	Venetoclax and Navitoclax in Combination with Chemotherapy in Patients with Relapsed or Refractory Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma. <i>Cancer Discovery</i> , 2021, 11, 1440-1453.	9.4	137
3	Treatment of posttransplant lymphoproliferative disorder with poor prognostic features in children and young adults: Short-course EPOCH regimens are safe and effective. <i>Pediatric Blood and Cancer</i> , 2021, 68, e29126.	1.5	5
4	Active and Protected: Developing a "Safer Sex" Handout for Adolescents and Young Adults with Cancer. <i>Journal of Adolescent and Young Adult Oncology</i> , 2021, 10, 351-354.	1.3	1
5	Brentuximab Vedotin As Consolidation Therapy Following Autologous Stem Cell Transplantation in Children and Adolescents with Relapsed/Refractory Hodgkin Lymphoma: A Multi-Center Retrospective Analysis. <i>Blood</i> , 2021, 138, 2465-2465.	1.4	2
6	Ibrutinib plus CIT for R/R mature B-NHL in children (SPARKLE trial): initial safety, pharmacokinetics, and efficacy. <i>Leukemia</i> , 2020, 34, 2271-2275.	7.2	9
7	Safety of Palbociclib in Combination with Chemotherapy in Pediatric and Young Adult Patients with Relapsed/Refractory Acute Lymphoblastic Leukemia and Lymphoma: A Children's Oncology Group Pilot Study. <i>Blood</i> , 2020, 136, 20-21.	1.4	5
8	Location of Death and End-of-Life Characteristics of Young Adults with Cancer Treated at a Pediatric Hospital. <i>Journal of Adolescent and Young Adult Oncology</i> , 2019, 8, 417-422.	1.3	6
9	V2 Trial: A Phase I Study of Venetoclax Combined with CPX-351 for Children, Adolescents and Young Adults with Relapsed or Refractory Acute Leukemia. <i>Blood</i> , 2019, 134, 3830-3830.	1.4	1
10	Safety and Efficacy of Venetoclax in Combination with Navitoclax in Adult and Pediatric Relapsed/Refractory Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma. <i>Blood</i> , 2019, 134, 285-285.	1.4	24
11	Collaborating with Adolescents and Young Adults with Cancer as Advisors. <i>Journal of Adolescent and Young Adult Oncology</i> , 2018, 7, 499-503.	1.3	3
12	Phase 1 trial of ontuxizumab (MORAb004) in children with relapsed or refractory solid tumors: A report from the Children's Oncology Group Phase 1 Pilot Consortium (ADVL1213). <i>Pediatric Blood and Cancer</i> , 2018, 65, e26944.	1.5	19
13	Venetoclax and Navitoclax in Patients with Relapsed or Refractory Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma. <i>Blood</i> , 2018, 132, 3966-3966.	1.4	5
14	A Phase I/Pilot Study of CPX-351 [Daunorubicin and Cytarabine Liposome for Injection (Vyxeos®)] for Children, Adolescents and Young Adults with Recurrent or Refractory Acute Leukemia. <i>Blood</i> , 2018, 132, 336-336.	1.4	0